Loading news...
Avis Budget Group Told Investors Adjusted EBITDA Rose 11% -- But GAAP Results Showed an $856 Million Net Loss NEW YORK, March 18, 2026 /PRNewswire/ -- Avis Budget Group (NASDAQ: CAR) reported adjusted EBITDA growth of 11% for Q4 2025. Under GAAP, the Company posted a net loss of $856 million.
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is currently chief medical officer at Cellectis, the French biotechnology company focused on allogeneic CAR-T therapies, which engineer a patient's immune cells to target and destroy cancer.
Caisse régionale de Crédit Agricole Mutuel d'Ille-et-Vilaine, société coopérative à capital variable, agréée en tant qu'établissement de crédit, Siège social : 4, rue Louis Braille - 35136 Saint-Jacques de la Lande, immatriculée au RCS de Rennes sous le n° 775 590 847. Société de courtage d'assurance immatriculée auprès de l'ORIAS sous le n°07 023 057.Titulaire de la carte professionnelle Transaction, Gestion Immobilière et Syndic n° CPI 3502 2021 000 000 001 délivrée par la CCI Ille-et-Vilaine, bénéficiant de la Garantie Financière et Assurance de Responsabilité Civile Professionnelle délivrées par CAMCA, 53 rue de la Boétie 75008 Paris.
Avis Budget Group Told Investors Adjusted EBITDA Rose 11% -- But GAAP Results Showed an $856 Million Net Loss Avis Budget Group Told Investors Adjusted EBITDA Rose 11% -- But GAAP Results Showed an $856 Million Net Loss
Avis Budget Group Posts $856 Million Net Loss as Revenue Falls Short of Expectations NEW YORK, March 4, 2026 /PRNewswire/ -- Avis Budget Group (NASDAQ: CAR) shareholders suffered significant losses after the company reported a Q4 2025 GAAP net loss of $856 million and revenue that missed analyst consensus estimates by approximately $80 million. If you lost money on your CAR investment, you are encouraged to obtain additional information and submit your details here.
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR) LYMPHIR was well-tolerated with no dose-limiting toxicities observed CRANFORD, N.J., March 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR‑T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma (DLBCL).
Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026. With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.
Insider buying can signal confidence when executives and major shareholders put their own money on the line.
Philadelphia, Pennsylvania--(Newsfile Corp. - March 1, 2026) - Kaskela Law LLC announces that it is actively investigating the recently announced proposed buyout of Mister Car Wash, Inc. (NASDAQ: MCW) shareholders to determine whether the $7.00 per share buyout offer is fair to the company's investors. On February 18, 2026, Mister Car Wash announced that it had agreed to be acquired by private equity investment firm Leonard Green & Partners L.P.
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- PLEASE READ THIS NOTICE CAREFULLY AND COMPLETELY. YOUR RIGHTS MAY BE AFFECTED.
New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Avis Budget Group, Inc. ("Avis Budget Group, Inc.") (NASDAQ: CAR) concerning potential violations of the federal securities laws. The Q4 2025 loss was driven in significant part by a material write-down of the company's electric vehicle fleet.
CAR shares plunge 21.8% after Q4 loss of $6.53 per share and revenue miss as Americas sales fall. The 2026 EBITDA guidance ranges from $800M to $1B.
ARR, ARI and DKNG have been added to the Zacks Rank #5 (Strong Sell) List on February 20th, 2026.
Avis Budget Group, Inc.'s Q4 2025 results were a broad miss: $2.66B revenue vs. $2.75B Street, FY25 revenue $11.65B, missing consensus for the third straight year. The big shock was profitability with FY25 adj. EBITDA is coming in at $748M vs. the original >$1B target (later cut to $900M–$1.0B), plus near-zero Q4 EBITDA vs. $157M guided. The international segment turned around in 2025 but still remains a minor revenue contributor (23% of Q4 revenue) vs. the Americas region.
Stocks are lower, holding on to earlier losses, as geopolitical tensions between the U.S. and Iran resurface
Avis Budget Group, Inc. (CAR) Q4 2025 Earnings Call Transcript
Avis Budget Group took a massive write-down on its EVs last quarter, tumbling the shares for a loss. Avis lost even more money in 2024 than in 2025, and might actually earn a profit in 2026.
Evaluate the expected performance of Avis Budget (CAR) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.